Phase I clinical trial - Sein

RadioPARP
Sein
Essai clinique fermé
Public cible
Adulte
A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Description de l'essai

Primary Outcome Measures: ÀDetermination of the Maximal Tolerated Dose of Olaparib administered with concurrent loco regional radiotherapy [ Time Frame: 2 years ];Incidence of early Dose Limited Toxicity (DLTs: early adverse effects related to Olaparib administered with concurrent radiotherapy) to determinate the Maximal Tolerated Dose (MTD) of Olaparib administered with concurrent loco regional radiotherapy in patients who have triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated patient with residual disease (after neoadjuvant chemotherapy).